SCF Therapeutic Development Program for Cystic Fibrosis
Program Code: SCF-CF-S1-0001
Development Classification: Multi-Target Disease-Modifying Therapeutic Platform
Disease Area: Cystic Fibrosis
Development Strategy: Adjunctive therapy to CFTR modulators and standalone therapy for modulator-nonresponsive patients
I. STAGE 1 OBJECTIVE
Transform the Stage 0 disease-origin analysis into a mechanistically integrated therapeutic hypothesis suitable for:
- API discovery
- Target validation
- Preclinical screening
- Translational planning
- IND-enabling development
The objective is not to replace CFTR modulators but to address residual disease mechanisms that continue driving pulmonary decline despite correction of CFTR dysfunction.
II. SCF ROOT CAUSE DECOMPOSITION
Primary Driver
CFTR Dysfunction
↓
Secondary Drivers
- Mucus dehydration
- Biofilm establishment
- Chronic neutrophilic inflammation
- Oxidative stress
- ECM destruction
- Progressive fibrosis
These secondary drivers become semi-autonomous disease loops even after partial CFTR restoration.
III. THERAPEUTIC HYPOTHESIS
SCF Central Hypothesis
A therapeutic platform simultaneously targeting:
- Biofilm persistence
- Neutrophil elastase activity
- NF-κB inflammatory signaling
- TGF-β fibrotic remodeling
- Nrf2-mediated redox protection
will produce greater preservation of pulmonary function than CFTR correction alone.
IV. SCF THERAPEUTIC ARCHITECTURE
Module A — Biofilm Collapse Engine
Biological Problem
Persistent airway biofilms protect pathogens from:
- antibiotics
- immune clearance
- mucociliary removal
Primary pathogens:
- Pseudomonas aeruginosa
- Burkholderia cepacia complex
Therapeutic Goal
Disrupt extracellular polymeric matrix.
Candidate Target Classes
Target | Rationale |
Quorum sensing pathways | Prevent biofilm maintenance |
Extracellular DNA | Biofilm structural integrity |
Alginate production | Pseudomonas persistence |
Biofilm proteases | Matrix destabilization |
SCF Role:
Target Modulator
Module B — Neutrophilic Damage Suppression
Biological Problem
Persistent neutrophil activation releases:
- elastase
- MMPs
- ROS
causing irreversible airway destruction.
Targets
Target | Function |
Neutrophil Elastase | Direct tissue injury |
CXCR2 | Neutrophil recruitment |
IL-8 | Inflammatory amplification |
SCF Role:
Safety Harmonizer
Module C — Anti-Fibrotic Reconstruction
Biological Problem
Progressive ECM remodeling drives:
- bronchiectasis
- fibrosis
- loss of lung elasticity
Targets
Target | Function |
TGF-β | Fibrosis driver |
SMAD signaling | Fibroblast activation |
MMP/TIMP balance | ECM regulation |
SCF Role:
Restorative Modulator
Module D — Bioenergetic Recovery
Biological Problem
Chronic inflammation induces:
- ATP depletion
- mitochondrial dysfunction
- ROS overload
Targets
Target | Function |
Nrf2 | Antioxidant defense |
Mitochondrial biogenesis | Energy restoration |
Glutathione pathways | Redox balance |
SCF Role:
Metabolic Regulator
V. SCF FIBONACCI THERAPEUTIC STACK
Based upon SCF stack design principles.
Role | Number | Function |
Target Modulator | 1 | Biofilm collapse |
Safety Harmonizer | 1 | Elastase suppression |
Metabolic Regulators | 2 | Nrf2 + mitochondrial support |
Absorption Enhancers | 3 | Pulmonary delivery optimization |
Supportive Agents | 5 | ECM, mucus, immune support |
VI. TARGET PRODUCT CONCEPT
Working Program Name
PROJECT AEROVIA-CF1
Therapeutic Class
Multi-target inhaled disease-modifying therapy
Intended Use
Add-on treatment to:
Trikafta
and future CFTR modulators.
Target Population
- Advanced pulmonary disease
- Chronic biofilm infection
- Persistent inflammation
- Modulator-nonresponsive mutations
VII. STAGE 1 TARGET PRIORITIZATION
Tier 1 Targets
Highest probability of clinical success:
- Neutrophil Elastase
- CXCR2
- TGF-β
- Nrf2
Tier 2 Targets
Medium-risk innovation targets:
- Biofilm quorum sensing
- Alginate synthesis
- Extracellular DNA networks
Tier 3 Targets
Long-term platform targets:
- Airway regeneration
- Stem-cell repair
- ECM reconstruction
VIII. BIOMARKER STRATEGY
Pharmacodynamic Biomarkers
Biomarker | Readout |
Neutrophil elastase | Tissue injury reduction |
IL-8 | Inflammation reduction |
TGF-β | Fibrosis control |
MMP-9 | ECM preservation |
ROS markers | Oxidative stress reduction |
Clinical Biomarkers
Endpoint | Importance |
FEV1 | Primary |
Lung Clearance Index | Early efficacy |
Exacerbation rate | Disease modification |
Hospitalization frequency | Clinical utility |
Sputum pathogen burden | Biofilm efficacy |
IX. STAGE 1 TRANSLATIONAL HYPOTHESIS
Preventative Component
Prevent establishment of chronic pathogen reservoirs.
Curative Component
Reduce inflammatory and microbial drivers.
Restorative Component
Reconstruct damaged ECM and restore mitochondrial resilience.
This aligns directly with the SCF PCR framework (Preventative–Curative–Restorative).
X. GO / NO-GO ASSESSMENT
Criterion | Result |
Biological Plausibility | GO |
Unmet Need | GO |
Biomarker Availability | GO |
Translational Feasibility | GO |
Regulatory Feasibility | GO |
Commercial Differentiation | GO |
STAGE 1 OUTCOME
APPROVED FOR STAGE 2
Stage 2 — Therapeutic Concept Design & Candidate Identification
Primary objective:
Generate and rank:
- Small-molecule APIs
- Biologic candidates
- Natural-product-derived APIs
- Inhaled therapeutic platforms
- SCF synergistic combination candidates
for preclinical development against:
- Biofilm persistence
- Neutrophilic inflammation
- Fibrotic remodeling
- Oxidative injury
- Mitochondrial dysfunction
Recommended Stage 2 Focus
Among all opportunities identified, the strongest differentiation potential lies in:
A first-in-class inhaled multi-target anti-biofilm + anti-elastase + anti-fibrotic therapeutic platform used alongside CFTR modulators.
MASTER REGISTRY INDEX
SCF-CF-S1-0001 — Cystic Fibrosis Therapeutic Hypothesis Engine
SCF-PATH-UT-0001 — SCF Pathophysiology Protocol
SCF-ETHBIO-WF-0001 — SCF Ethnobioprospecting Workflow
SCF-SEF-MD-0001 — Synergistic Evaluation Framework
SCF-API-DP-0001 — SCF API Discovery Profile Template
SCF-FDA-IND-0001 — FDA Translational Development Framework